TrialThe Lancet. Oncology2013

Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial.

Thomas Crosby et al.PubMed ↗Publisher ↗

No numbers read from the abstract.